Laurion Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Laurion Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-19,045	Closed	-$343K	–	1043
2020 Q3	$343K	Buy	+19,045	New	+$394K	﹤0.01%	640
2018 Q2	–	Sell	-11,754	Closed	-$112K	–	1681
2018 Q1	$112K	Buy	+11,754	New	+$127K	﹤0.01%	1270

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Laurion Capital Management's DRNA Position: Q4 2020 in Review

Laurion Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2020, closing a stake of 19,045 shares — an estimated $343K sold.

Laurion Capital Management first reported a position in DRNA in Q1 2018 and held it in 2 quarters. The position peaked at $343K in Q3 2020. 173 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

Laurion Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Laurion Capital Management sold 19,045 Dicerna Pharmaceuticals, Inc. shares in Q4 2020, an estimated $343K.
Laurion Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
Laurion Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $343K in Q3 2020.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2020.

Based on Laurion Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.